Type 2 Diabetes

Data from the REWIND trial suggests men receiving dulaglutide had an 8% lower risk for incident erectile dysfunction than their counterparts who were randomized to placebo therapy.

An analysis of contemporary trends related to preventive aspirin use suggests older patients with diabetes were twice as likely to use preventive aspirin as their counterparts without diabetes, with many doing so despite it being considered inappropriate based on new guidance.

Using 24 years of follow-up data from more than 12k adolescents provides insight into the impact of childhood BMI z-scores on risk of adverse health outcomes, including development of diabetes and premature myocardial infarction, in adulthood.

Panelists consider the importance of long-term approaches to monitoring hypoglycemic episodes and discuss the role of education and awareness, patient questionnaires, and effective communication with physicians.

Key opinion leaders in diabetes comment on various blood glucose tests to assess hypoglycemia and prevent future episodes.

Using data from within NHANES from 2011-2018, investigators from Johns Hopkins University provide a comprehensive overview of the use of aspirin for primary and secondary prevention among older patients based on diabetes status.

Drs Marc P. Bonaca and Manesh R. Patel discuss the rationale for individualized treatment plans for patients with type 2 diabetes at high risk for cardiovascular disease.

Implications for treating patients at risk of cardiovascular disease with rivaroxaban plus aspirin based on the COMPASS and VOYAGER PAD clinical trials.

Comparing data from patients with primary nephrotic syndrome to matched controls in a 1:100 ratio, investigators found these patients were at a 19-fold greater risk of end-stage kidney disease and a 3-fold greater risk of acute coronary syndrome events.

New research from the Joslin Diabetes Center details the impact of comorbidities on quality of life in patients with type 1 diabetes.

Improvements in neovascularization and best-correct visual acuity were generally not sustained following treatment discontinuance.

A multidisciplinary panel of experts shares insights into identifying symptoms of hypoglycemia and highlights the importance of stratifying level 1, 2, and 3 blood glucose levels when making the differential diagnosis in diabetes.

Expert panelists provide an overview of health complications associated with mild and severe hypoglycemic episodes and emphasize the importance of patient awareness and early recognition to improve quality of life and health-related outcomes.

Recommendations for treating patients with coronary artery disease and type 2 diabetes with dual antiplatelet therapy based on data revealed by the THEMIS trial.

Strategies used to help determine patients’ risk for cardiovascular disease and the role of lifestyle management in helping reduce the risk for events in patients with type 2 diabetes.

Data from the UK Biobank cohort details the increased risk of adverse health outcomes, including the development of diabetes and heart failure, among patients considered to have metabolically healthy obesity.

A systematic review details the impact of topical agents for the treatment of diabetes-related ophthalmic conditions, such as diabetic macular edema and diabetic retinopathy.

A comparison of women with PCOS to matched controls indicates women with PCOS were at a 26% greater risk of experiencing major adverse cardiovascular events than their counterparts without polycystic ovary syndrome.

Reported HRQOL remains consistent in youth with T1D, but multiple comorbidities and mental health conditions linked to decline.

Dapagliflozin and the SGLT2 inhibitor class may have untapped potential far beyond the reduction of heart failure hospitalization risk.

A cross-sectional analysis of NHANES data paints a grim picture related to rates of patients with diabetes achieving goals for glycemic, blood pressure, and lipid control.

A systematic review of clinical trials notes that topical eye drops may lead to favorable retinal and visual outcomes, despite heterogeneity across multiple studies.

An expert discussion on the recent FDA committee decision to support teplizumab in delaying clinical type 1 diabetes.

An analysis of data from nearly 500k patients suggests patients with diabetes experiencing frequent insomnia were at an 87% increased risk of all-cause mortality compared to those with neither sleep disturbances nor diabetes.

Thought leaders in diabetes provide closing remarks about the importance of continuous awareness of glycemic control in patients as well as the need for effective communication between patients and providers.